Articles

In this salty take on Hyatt Hotels Corporation's latest venture, we roast the opening of the Hyatt Regency Zhuhai Gongbei with due diligence flair. Factual digs into its features, location, and what it means for the hospitality grind – all while keeping it real, no BS promises.

Hershey is pivoting hard into salty snacks to hit 20% of revenue, dodging cocoa price punches and health-conscious consumers. But with growth sputtering and margins getting squeezed, is this diversification a smart play or just desperate flailing? A salty take on the candy giant's latest move.

A salty, no-holds-barred due diligence on the iShares Environmentally Aware Real Estate ETF (ERET), roasting its near-term hype against long-term meh vibes, with a side of sarcasm on those AI trading strategies that promise the world but deliver pocket change.

A salty take on Netgear's Nighthawk routers, roasting the hype around WiFi 6 upgrades while grounding it in real user gripes and features that might actually fix your home's internet hellscape.

A salty take on DTE Energy's latest tweaks to executive incentives, roasting the metrics that keep the C-suite bonuses flowing while questioning if shareholders are getting the short end of the stick.

In a move that's got the ag world buzzing, John Deere is yanking back nearly 250 laid-off workers in Iowa to crank out more tractors and gear amid 'rising demand.' But let's salt this up: is this a comeback story or just corporate whiplash in a bumpy farm economy? We roast the details without the fluff.

In a move that's equal parts genius and 'we're sinking, send help,' AMD snags Ariel Kelman from Salesforce as their new CMO. We roast the hire, dissect the drama, and wonder if better ads will finally make those EPYC processors pop—without the hype, just salty facts.

In a move that's equal parts heartwarming and eyebrow-raising, HCA Healthcare's TriStar Health drops $150K to help Middle Tennesseans battered by Winter Storm Fern. But let's peel back the layers on this 'generous' act in the cutthroat world of for-profit healthcare.

In this salty opinion piece, we roast American Electric Power's upcoming Q4 earnings projections, where EPS dips 7.3% despite an 11.4% revenue bump. Expect mixed segment vibes and a whole lot of utility-sector snark, all grounded in analyst forecasts.

In this opinion piece, we dive into Cardinal Health's role in distributing SQ Innovation's Lasix ONYU, a home-based furosemide injection for heart failure patients. While the deal expands access, we roast the healthcare distribution game's usual suspects—bureaucracy, pricing woes, and the endless quest for affordability—with a factual, no-BS lens.

A salty take on DuPont's upcoming Q4 earnings, dissecting the spinoff's first real test amid analyst optimism, profitability questions, and lingering PFAS headaches.

In this salty take on Ulta Beauty's all-time high stock price, we roast the cosmetics giant's meteoric rise, dissect its growth plays, and question if the shine is skin-deep—all while keeping it real with the facts.

In a classic case of too little too late, HSBC upgrades JPMorgan Chase from 'Reduce' to 'Hold' with a $319 price target, citing the stock's brutal underperformance. We dive into the saltiness of it all, from strong Q4 numbers to weird side gigs like Jersey Mike's IPO, all while roasting the obvious.

A salty take on PPG Industries' latest analyst rating, roasting the paint giant's gains amid macro uncertainties while keeping it real with the facts.

In a market obsessed with flashy tech and meme coins, Energy Transfer LP (ET) gets slapped with the 'undercovered' label. This salty dive roasts the midstream giant's unglamorous grind, from dividend drama to pipeline politics, all while staying brutally factual.

In this opinion piece, we dive into the recent sell-off of Invesco QQQ shares by Shepherd Wealth Management with a hefty dose of sarcasm and facts. While one firm lightens up, others pile in—classic market chaos that screams 'pick your poison' without us telling you what to do.

A salty, no-holds-barred roast of Taiwan's blunt rejection of US demands to relocate 40% of its semiconductor powerhouse to American turf, spotlighting TSM's unshakeable dominance and the geopolitical clown show that follows.

In this salty opinion piece, we roast the recent fund sell-off in Amgen ($AMGN) amid strong earnings and dividend hikes, questioning if the cuts are smart or just panic, all while keeping it factual and meme-tinged.

In a move that's equal parts optimistic and eyebrow-raising, CCORF analyst Madeleine Williams sticks to her guns with a buy rating on Mesoblast Ltd. (MEOBF.US), bumping the price target up to $2.33. We dive into this with all the salt it deserves, roasting the biotech's bumpy ride while keeping it real—no diamond hands required.

Intercontinental Exchange launches new futures tied to the Korean market, but with solid revenues hiding some score-based red flags, is this a savvy expansion or a salty side quest?

In a classic case of hype meeting harsh reality, Boston Scientific's (BSX) latest earnings report has sparked a fraud investigation and a brutal stock plunge. This opinion piece roasts the company's missteps in its key growth segment while keeping it real with the facts—no diamond hands needed here.

In a move that's got the trading tech world buzzing, Broadridge Financial Solutions is set to acquire CQG's core business. This opinion piece roasts the deal with salty due diligence, questioning if it's a smart power-up or just another bloated acquisition in a crowded market.

A salty take on Jack Henry & Associates (JKHY) amid Fiserv's upcoming earnings flop, roasting the fintech world's sleepy giants with facts, sarcasm, and a dash of due diligence.

In a move that's equal parts bold and eyebrow-raising, AIG shells out over $2.7 billion for stakes in Convex and Onex. This salty opinion piece dissects the deal's guts, roasts the risks, and questions if it's a savvy pivot or just another insurance headache.

A humorous yet factual roast of the Ft Vest Dow Jones Internet & Target Income ETF (FDND), highlighting its weak near- and mid-term sentiment amid elevated risks, while poking fun at the institutional strategies that might just save your bacon – or not.

In a move that's equal parts corporate housekeeping and eyebrow-raising exclusion, News Corp announces a $1 billion share repurchase program for its U.S. stocks, snubbing ASX-listed interests. We dive into the salty details of this capital return strategy, questioning if it's a savvy play or just another layer of the media mogul's convoluted empire management.

A salty dive into Consolidated Edison's latest Brooklyn blackout blunder, where snow and salt team up to leave residents in the dark—again. We roast the utility giant's reliability woes without pulling punches, all while keeping it real with the facts.

A salty take on Church & Dwight Co Inc (CHD), roasting its everyday essentials empire while admitting the unflashy truth: in a world of meme-stock madness, this baking soda and condom king might just be the steady eddy investors sleep on.

Ford's shifting gears to a 'capability'-focused marketing blitz for 2026, ditching the patriotic vibes of 2025 amid a sea of recalls and quality gripes. Is this a smart pivot or just lipstick on a rusty pig?

U.S. Bancorp (USB) exceeded earnings and revenue expectations for fiscal 2025, hit a new 52-week stock high, and announced a leadership transition. This opinion piece roasts the bank's performance and executive changes with sarcasm, staying grounded in facts.

Jabil Inc. is doubling down on India with new facilities in Pune and Gujarat, aiming to tap into global supply chain shifts and local growth. But is this strategic genius or a salty reminder of how companies scramble for relevance? We roast the facts without the fluff.

A salty take on National Bankshares' impressive 45% total shareholder return, roasting the sleepy bank's performance while questioning if the hype matches the reality. Dividends and EPS growth steal the show, but is this a diamond or just another regional yawn?

In this salty take, we roast the 'boring' world of Genuine Parts Company (GPC), a steady eddy in the choppy seas of stocks. While meme-chasers get wrecked, GPC quietly stacks cash through auto parts and dividends. Factual due diligence with a side of sarcasm – because stability shouldn't be this infuriatingly reliable.

A salty dive into VICI Properties' unshakeable fundamentals and ironclad balance sheet, where analysts keep simping despite the market's endless chaos. We roast the stability that's equal parts yawn and win.

Pfizer's latest licensing deal with Roivant Sciences has everyone buzzing about brepocitinib, but is it really the miracle drug it's hyped up to be? Let's dive into the salty details.

This article humorously examines the bullish outlook for CoStar Group (CSGP) following its sales force expansion, while maintaining a grounded perspective on the company's future performance.